Advertisement

CEN Case Reports

, Volume 8, Issue 2, pp 95–100 | Cite as

Clinical usefulness of serum levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio to rule out preeclampsia in women with new-onset lupus nephritis during pregnancy

  • Chikako Hirashima
  • Manabu Ogoyama
  • Miyuki Abe
  • Satoru Shiraishi
  • Taro Sugase
  • Toshiro Niki
  • Shigeki Matsubara
  • Akihide OhkuchiEmail author
Case Report
  • 58 Downloads

Abstract

Measurement of the soluble fms-like tyrosine kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio may be clinically useful to discriminate systemic lupus erythematosus (SLE) from preeclampsia. Here, we present a pregnant woman with new-onset SLE with hypertension, with the measurement of the sFlt-1/PlGF ratio during pregnancy. A 31-year-old Japanese nulliparous woman, who had been diagnosed with idiopathic thrombocytopenic purpura at 10 years, had a systolic blood pressure of 120 mmHg and was negative for proteinuria at 12+1 weeks. Since her blood pressure increased to 159/86 mmHg with 3+ proteinuria at 25+4 weeks, preeclampsia was suspected. Deterioration of the kidney function (creatinine: 0.58 mg/dL at 24+6 weeks to 0.83 mg/dL at 33+6 weeks) necessitated cesarean section at 33+6 weeks. After delivery, she still showed increased creatinine and proteinuria. Therefore, she was transferred to a nephrology specialist in a tertiary center and was finally diagnosed with SLE with lupus nephritis class IV-G(A) (diffuse lupus nephritis). The serum levels of sFlt-1 and the sFlt-1/PlGF ratio, which are usually elevated in preeclampsia, were within normal reference ranges at 27+6, 28+1, and 28+6 weeks of gestation, although the serum levels of PlGF were slightly lower than the normal reference range. In conclusion, measurement of the sFlt-1/PlGF ratio may be clinically useful to discriminate lupus nephritis from preeclampsia.

Keywords

Lupus nephritis Placental growth factor Preeclampsia Pregnancy Soluble fms-like tyrosine kinase 1 Systemic lupus erythematosus 

Notes

Acknowledgements

We thank Roche Diagnostics K. K. for the offer of reagents (sFlt-1 and PlGF), and the measurements of sFlt-1 and PlGF conducted free of charge under collaborative research with Roche Diagnostics K. K. (I-12-78.) Toshimitsu Ohtani, Kanako Nakamura, Chihiro Kamosawa, Keizou Yoshida, and Hideki Yano of Nasu Red Cross Hospital contributed to the detection and diagnosis of SLE.

Funding

None.

Compliance with ethical standards

Conflict of interest

Measurements of serum levels of sFlt-1, PlGF, and the sFlt-1/PlGF ratio in this case were performed in collaborative research with Roche Diagnostics K. K. (I-12-78.)

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number: I-12-78) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. We also obtained written informed consent for this case report from the patient.

Informed consent

We also obtained written informed consent for this case report from the patient.

References

  1. 1.
    Shiozaki A, Matsuda Y, Satoh S, Saito S. Comparison of risk factors for gestational hypertension and preeclampsia in Japanese singleton pregnancies. J Obstet Gynaecol Res. 2013;39:492–9.CrossRefGoogle Scholar
  2. 2.
    Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33:196–205.CrossRefGoogle Scholar
  3. 3.
    Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, Xu H, Yang N. New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol. 2013;32:815–22.CrossRefGoogle Scholar
  4. 4.
    Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology. 2002;41:643–50.CrossRefGoogle Scholar
  5. 5.
    Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13–22.CrossRefGoogle Scholar
  6. 6.
    Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, Ferraresi M, Todros T, Piccoli GB. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83:177–81.CrossRefGoogle Scholar
  7. 7.
    Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006;194:551–6.CrossRefGoogle Scholar
  8. 8.
    Mayer-Pickel K, Stern C, Eberhard K, Lang U, Obermayer-Pietsch B, Cervar-Zivkovic M. Angiogenic factors in pregnancies of women with antiphospholipid syndrome and systemic lupus erythematosus. J Reprod Immunol. 2018;127:19–23.CrossRefGoogle Scholar
  9. 9.
    Leaños-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, Molina-Pérez CJ, García-Paleta Y, Isordia-Salas I, Ramírez-Valenzuela KL. Circulating angiogenic factors and the risk of preeclampsia in systemic lupus erythematosus pregnancies. J Rheumatol. 2015;42:1141–9.CrossRefGoogle Scholar
  10. 10.
    Qazi U, Lam C, Karumanchi SA, Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol. 2008;35:631–4.Google Scholar
  11. 11.
    Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefGoogle Scholar
  12. 12.
    Hartman EAR, van Royen-Kerkhof A, Jacobs JWG, Welsing PMJ, Fritsch-Stork RDE. Performance of the 2012 Systemic Lupus International Collaborating Clinics classification criteria versus the 1997 American College of Rheumatology classification criteria in adult and juvenile systemic lupus erythematosus. A systematic review and meta-analysis. Autoimmun Rev. 2018;17:316–22.CrossRefGoogle Scholar
  13. 13.
    Suzuki H, Hirashima C, Nagayama S, Takahashi K, Yamamoto T, Matsubara S, Ohkuchi A. Increased serum levels of sFlt-1/PlGF ratio in preeclamptic women with onset at < 32 weeks compared with ≥ 32 weeks. Pregnancy Hypertens. 2018;12:96–103.CrossRefGoogle Scholar
  14. 14.
    Suzuki H, Nagayama S, Hirashima C, Takahashi K, Takahashi H, Ogoyama M, Nagayama M, Shirasuna K, Matsubara S, Ohkuchi A. Markedly higher sFlt-1/PlGF ratio in a woman with acute fatty liver of pregnancy compared with HELLP syndrome. J Obstet Gynaecol Res. 2018.  https://doi.org/10.1111/jog.13786.Google Scholar
  15. 15.
    Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Arai F, Watanabe T, Kario K, Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 2007;30:151–9.CrossRefGoogle Scholar
  16. 16.
    Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010;33:422–7.CrossRefGoogle Scholar
  17. 17.
    Ohmaru T, Ohkuchi A, Muto S, Hirashima C, Matsubara S, Suzuki M. Increased antiangiogenetic factors in severe proteinuria without hypertension in pregnancy: is kidney biopsy necessary? CEN Case Rep. 2014;3:86–9.CrossRefGoogle Scholar
  18. 18.
    Ohkuchi A, Hirashima C, Matsubara S, Suzuki H, Takahashi K, Usui R, Suzuki M. Serum sFlt1:PlGF ratio, PlGF, and sEng levels in gestational proteinuria. Hypertens Pregnancy. 2009;28:95–108.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyJichi Medical University School of MedicineShimotsukeJapan
  2. 2.Department of Obstetrics and GynecologyNasu Red Cross HospitalOtawaraJapan
  3. 3.Division of Nephrology, Department of Internal MedicineJichi Medical UniversityShimotsukeJapan
  4. 4.Division of Integrative PathologyJichi Medical UniversityShimotsukeJapan

Personalised recommendations